In the News
The mixed public-private effort with Vaccinex is aiming to bring about a treatment for intractable osteosarcoma.
A public-private collaboration between University of Minnesota researchers and a clinical-stage biotech company making an experimental anti-cancer drug has resulted in a new push for an immunotherapeutic treatment against childhood bone cancer.
TriKE and TetraKE Platforms to be Highlighted
LOS ANGELES, February 13, 2018 /PRNewswire/ --
CAMBRIDGE, Mass., January 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.
SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment.
Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14
No Dose Limiting Toxicities Reported
SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.
Douglas Yee, MD, and colleagues from various cancer centers around the country, recently met with Senator Dianne Feinstein of California, and a number of other senators, to discuss NIH funding for cancer research.
With important budget decisions taking place in Washington in the coming weeks, the group met with the members of Congress to stress the importance of the NIH and the funding that it provides for continued cancer research efforts.
There has been great interest in finding structural targets in cancer for the widely prescribed type 2 diabetes drug metformin. Metformin is a synthetic product derived from galegine, a guanide natural product found in French lilac. Documented use of galegine for human disease dates back to 1620, when John Parkinson first described the use of lilac plants for medicinal purposes in his treatise Theatrum Botanicum.
